echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 12:1! Novaral's heavy heart failure drug, Nohinto, has received support from the FDA Advisory Committee to expand its scope of application

    12:1! Novaral's heavy heart failure drug, Nohinto, has received support from the FDA Advisory Committee to expand its scope of application

    • Last Update: 2020-12-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    HFpEF affects more than 3 million Americans, and as society ages, the prevalence rate is increasing.
    despite decades of research, it is difficult to develop treatments because of the heterogeneous nature of pathophysiology and the different effects of patient symptoms.
    HFpEF can alter the structure of the heart, which occurs when the heart's muscle tissue thickens and hardens so that it cannot expand to fill up with enough blood to meet the body's needs.
    HFpEF was associated with high rates of relapse to heart failure, emergency visits and emergency doctor appointments.
    hospitalization was associated with a long-term prognosis deterioration, with about a quarter of patients admitted again for heart failure within a year of discharge.
    Entresto has been approved in 115 countries around the world to treat reduced blood score heart failure (HFrEF).
    in China, where it was approved for listing in 2017.
    Entresto is a combination of the brain morphine enzyme inhibitor shakubaquo and the angiotensin-stressor antagonist python, which work better together.
    the other hand, through shakubaquo to enhance the beneficial role of nitrate peptide system, play a role in the diuretic, diastolic blood vessels and protect the heart and so on.
    the other hand, the role of renin-angiotensin-aldosterone (RAAS) is inhibited through salatin, which acts as a trachea, improves sodium retention and reduces heart load. the
    Committee's positive decision was based on an analysis of comprehensive data on Theresto efficacy and safety, including paramount-HF and Phase 2 clinical trial PARAMOUNT data in phase 3 clinical trials conducted in HFpEF patients, and Phase 3 clinical trial data in HFrEF patients.
    PARAGON-HF data show that Entersto has good safety characteristics in HFpEF patients, consistent with a large number of clinical and post-market experiences in HFrEF patients, and demonstrates Entersto's clinical benefits in HFpEF patients.
    resources: novartis announces positive FDA Advisory Committee recommendation for use of entresto® to treat patients with HFpEF. Retrieved December 16, 2020, from。
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.